Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Short Interest Update

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 5,100,000 shares, an increase of 7.8% from the October 15th total of 4,730,000 shares. Currently, 25.2% of the company’s stock are short sold. Based on an average daily volume of 191,600 shares, the days-to-cover ratio is presently 26.6 days.

Dianthus Therapeutics Stock Performance

DNTH stock opened at $23.60 on Tuesday. The business has a 50 day moving average price of $27.50 and a two-hundred day moving average price of $26.70. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The company had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Equities research analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Wedbush decreased their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, August 9th. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. Robert W. Baird assumed coverage on Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 price objective for the company. Raymond James increased their price objective on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Dianthus Therapeutics currently has an average rating of “Buy” and an average price target of $46.43.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Bain Capital Life Sciences Investors LLC bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $89,761,000. RA Capital Management L.P. bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $69,990,000. State Street Corp boosted its stake in shares of Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after acquiring an additional 413,425 shares during the period. Vanguard Group Inc. boosted its stake in shares of Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares during the period. Finally, Janus Henderson Group PLC bought a new position in shares of Dianthus Therapeutics during the 1st quarter worth approximately $11,251,000. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.